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Received November 16, 2014; accepted November 26, 2014AbstractIn late December 2013, a deadly infectious epidemic, Ebola virus disease (EVD), emerged from West Africa and resulted in a formidable
outbreak in areas including Guinea, Liberia, Sierra Leone and Nigeria. EVD is a zoonotic disease with a high mortality rate. Person-to-person
transmission occurs through blood or body fluid exposure, which can jeopardize first-line healthcare workers if there is a lack of stringent
infection control or no proper personal protective equipment available. Currently, there is no standard treatment for EVD. To promptly identify
patients and prevent further spreading, physicians should be aware of travel or contact history for patients with constitutional symptoms.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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On December 26, 2013, a 2-year-old child in the remote
Guinean village of Meliandou fell ill with a mysterious malady
characterized by fever, black stools, and vomiting.1 The small
male child passed away from his illness 2 days thereafter. In
the months following that case, thousands of people living in
Guinea, Liberia and Sierra Leone also died with similar
symptoms.2 The pathogen of the outbreak was identified, and
recalled the tragic circumstances of more than 30 years ago e
the onset of the Ebola virus.
In 1976, a new filovirus was identified in Zaire (now the
Democratic Republic of Congo [DRC]) and was named Ebola
after the River Ebola in the DRC. The mortality rate caused by
the virus was around 90%.3,4 Although medical facilities haveConflicts of interest: The authors declare that there are no conflicts of interest
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Africa was still more than 50% in 2014.5 The emergence of
the outbreak of EVD in West Africa shared common features
with the outbreak in 1976. Both were caused by Zaire ebo-
lavirus and began in rural forest communities. Critically-ill
patients were brought to provincial hospitals with vague sys-
temic presentations, causing hospital staff to be unaware of the
risks of being exposed to patient blood and body fluids without
proper protection and which inevitably worsened the out-
breaks.1,6 Furthermore, cases associated with locally infected
patients who travelled out of the West Africa region had been
identified in Senegal, Nigeria, Spain, and even the United
States.7 Due to the pervasive travel and general international
contacts implicit in globalization, as well as the popularity of
tourism, EVD is most certainly a threat to Taiwan.2. Virology
Ebola virus is an enveloped, negative single strand RNA
virus. It belongs to the virus family Filoviridae, also including
Cuevavirus and Marburg virus, with the characteristicociation. All rights reserved.
Table 1
Chronological list of outbreaks of Ebola virus disease in Africa.
Years Country Subtype Estimated
mortality rate
1976 Zaire (Democratic
Republic of Congo)a
Zaire 88%
South Sudan Sudan 53%
1977 Zaire Zaire 100%b
1979 South Sudan Sudan 65%
1994 Gabon Zaire 60%
Co^te d'Ivoire (Ivory Coast) Tai Forest 0%b
1995 Democratic Republic of
Congo (formerly Zaire)
Zaire 81%
1996 Gabonc Zaire 57%
Gabonc Zaire 75%
South Africa Zaire 50%
2000 Uganda Sudan 53%
2001 Gabon Zaire 82%
Republic of Congo Zaire 75%
2002 Republic of Congo Zaire 90%
2003 Republic of Congo Zaire 83%
2004 South Sudan Zaire 41%
2007 Democratic Republic of Congo Zaire 71%
Uganda Bundibugyo 25%
2008 Democratic Republic of Congo Zaire 47%
2011 Uganda Sudan 100%b
2012 Ugandac Sudan 36%d
Democratic Republic of Congo Bundibugyo 36%d
Ugandac Sudan 50%d
2014 West Africa (including Guinea,
Liberia, Sierra Leone, and Nigeria)e
Zaire 36%
Democratic Republic of Congof Zaire 74%
a The first episode of Ebola outbreaks.
b Only one defined case.
c Different time and towns in the same country.
d Laboratory confirmed cases only.
e Defined cases were also found in United States, Spain, Mali and Senegal.
f Unrelated to outbreak in West Africa.
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as a fifth-category notifiable communicable disease in Taiwan,
along with such other diseases as the Marburg virus.9 The
genus Ebola viruses are divided into five subtypes: Zaire
(EOBV), Sudan (SUDV), Bundibugyo (BDBV), Tai Forest
(TAFV) and Reston (RESTV).10 All but RESTV cause disease
in humans and each subtype has different biologic character-
istic and virulence.8,11
The exact origin, location, and natural reservoir of Ebola
virus remain unclear, although it is believed that the virus is
zoonotic and fruit bats may be the culprits of dissemination.8
According to epidemiological investigations, the previous area
of EVD outbreak overlapped with fruit bat territory.12 In Af-
rica, Hypsignathus monstrosus, Epomops franqueti and Myo-
nycteris torquata are considered the natural hosts of the Ebola
virus.8 In addition, some primates, such as apes or monkeys,
can also get infected.13 In general, if people have contact with,
or eat the infected reservoir of an infected animal, they may
get infected.14 However, in order for any larger scale person-
to-person transmission to occur (as in the past Ebola
outbreak), the virus would have to spread through the blood or
body fluids, including but not limited to urine, saliva, sweat,
feces, vomitus, breast milk, and semen, as well as via
contaminated objects like needles and syringes.3,14 The Ebola
virus is not spread through the air or by water, or by food in
general. Currently, there is no evidence that mosquitoes or
other insects can transmit Ebola virus.14 Once a person is
infected by the Ebola virus, there is no infectivity until the
onset of symptoms.15 The infectious doses for Ebola virus
disease is relatively high, frequently in the range of 107 to
108 pfu/g.8 The viral load increases as the disease becomes
worse. Therefore, the infectivity of patients with Ebola virus
disease is not as high as expected in the early stage. However,
the amount of viral particles originating from patients at the
later stage of Ebola is extremely high and will easily infect
persons without proper protection.
3. Epidemiology
The first case of the Ebola virus disease was recognized in
1976, and caused an outbreak in northern Zaire. The subtype
was named Zaire Ebola Virus (EOBV).3 At the same time,
another unrelated virus, which resulted in epidemics in south
Sudan, 850 kilometers away from Zaire, was identified as
Sudan Ebola Virus (SUDV).16 SUDV recurred in the same area
of Sudan in 1979.17 After two decades of silence, Ebola hem-
orrhagic fever re-emerged in 1994e1997 in DRC (formerly
Zaire) and Gabon.18,19 During the early 21st-century, smol-
dering outbreaks of EOBVand SUDVwere reported in Uganda
20 and Congo.21 The mortality rates for EOBVand SUDVwere
on average 80e90% and 50%, respectively.8 In 1994, a new
serotype of Ebola virus was identified from a patient and a
chimpanzee in Ivory Coast. The serotype, affecting a single
non-fatal case, was first named the Co^te d'Ivoire ebolavirus and
then renamed the Tai Forest Virus (TAFV).10,22 The fourth
Ebola virus subtype, Restonvirus (RESTV),which had resulted
in nonhuman primate outbreaks, was first identified in theUnited States during 1989e1990.23 In 1992, another outbreak
occurred in Italy. Both events were related to the importation of
monkeys from the Philippines.24 In 2008, there was a notice-
able increase of cases of porcine reproductive and respiratory
syndrome (PRRS) caused by RESTV in the Philippines and
China. The diseasewas characterized by highmortality in sows
and piglets. Fortunately, although the animal farmer workers
might become seropositive, the infection was asymptomatic
and there were no human deaths.11 In 2007, an outbreak of
hemorrhagic fever occurred in Uganda and was caused by the
fifth Ebola virus subtype, Bundibugyo virus (BDBV).20
Another outbreak caused by BDBV occurred in DRC in
2012.25 The mortality rate was around 40%, lower than the
previous two serotypes.8 It is worthmentioning that in 2014, the
outbreak of hemorrhagic fever in West Africa and DRC were
caused by EOBV, although the two outbreaks were unrelated.26
Owing primarily to the mechanisms of travel-related and
healthcare transmission, the EVD was also found in United
State, Spain, Mali, Senegal and Nigeria (Table 1). Fortunately,
with the assistance of sufficient infection control, the EVD
outbreaks in Senegal and Nigeria were declared over on
October 17 and October 19, 2014, respectively.7
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EVD has an incubation period of 2 to 21 days (mean,
4e10 days), and the infection is acute without any carrier status.
Symptoms usually begin with a flu-like syndrome, including
sudden onset of high fever, chills and myalgia. Multiple systems
may be involved, including gastrointestinal (anorexia, nausea,
vomiting, abdominal pain, diarrhea), respiratory (chest pain,
dyspnea, cough), vascular (conjunctival injection, postural hy-
potension, edema) and neurologic (headache, confusion and
coma) manifestation. A macropapular rash associated with
varying severity of erythema and desquamate can often be noted
by day 5e7 of the illness. Hemorrhagic manifestations arise
during the peak of the illness and include petechiae, ecchymoses,
uncontrolled oozing from venepuncture sites, mucosal hemor-
rhages, and post-mortem evidence of visceral hemorrhagic ef-
fusions. Hemorrhages can be severe but are present in less than
half of the affected patients. Those patients with fatal disease
develop clinical signs early during infection and die typically
between day 6 and 16 with hypovolemic shock and multi-organ
failure. Among non-fatal cases, patients have fever for several
days and improve typically around day 6 to 11.4,8
The Ebola virus enters the host through mucosal surfaces,
skin defect, or by parenteral introduction.3,8,16,19 The virus has
a broad cell tropism, affecting monocytes, macrophages,
dendritic cells, endothelial cells, fibroblasts, hepatocytes, ad-
renal cortical cells, and several types of epithelial cells.
Initially, the virus replicates in monocytes, macrophages, and
dendritic cells. Due to the subsequent carriage of these cells,
the virus disseminates to regional lymph nodes through the
lymphatic system and to the liver and spleen through the
blood.8,27e30 Various degrees of hepatocellular necrosis
resulted in decreased synthesis of coagulation and other
plasma proteins. The phenomenon is consistent with dissem-
inated intravascular coagulation (DIC) and may be related to
hemorrhagic tendencies.4,8,16,28 But, massive blood loss is
infrequent and, if present, is mainly limited to the gastroin-
testinal tract. Even in these cases, the amount of blood loss is
not sufficient to cause death.3,8 Adrenocortical infection and
necrosis causes impaired steroid synthesis and may lead to
hypotension and hypovolemia, which plays an important role
in the late stages of hemorrhagic fever.4,8,28
5. Diagnosis
The EVD usually presents as an acute viral prodrome and
many differential diagnoses should be considered, such as
malaria, typhoid fever, yellow fever and meningococcal
meningitis, which are also endemic diseases in Africa.4,8
Therefore, it is important to trace the travel and exposure
history when approaching a suspected patient returning from
an endemic area.
Laboratory diagnosis for EVD should be performed in a
well-equipped laboratory with up to biosafety level 4 bio-
contaminant facilities for viral culturing. In Taiwan, EVD is a
fifth-category notifiable communicable disease and should be
reported to the Taiwan Centers of Disease Control (CDC)within 24 hours. The characteristics that define reported EVD
include: 1. Clinical conditions which met any one of the
following: (1) acute febrile illness (38C) (2) headache,
myalgia, nausea, vomiting, diarrhea and abdominal pain, (3)
bleeding with unknown reason, and (4) sudden death with
unknown reason; 2. Laboratory conditions, with any of the
following: (1) clinical specimen (throat swab or skin biopsy)
that were isolated and identified as Ebola virus, (2) clinical
specimen that show positive by reverse transcription-
polymerase chain reaction (RT-PCR), and (3) serology
(enzyme link immunosorbent assays, IgM and IgG) positive; 3.
Epidemiologic conditions, with any of the following 21 days
before onset of symptoms: (1) history of travel from or living in
the endemic area of EVD, (2) exposure of blood, body fluids or
discharge pollutants from possible or defined cases, (3) history
of contact with bats, rodents, or primates in endemic area of
EVD, (4) operate the specimen of EVD in a laboratory. Once
the case fulfills clinical and epidemiologic conditions or any
laboratory benchmark, the patient should be reported to the
Taiwan CDC within 24 hours. If the first report is negative but
the patient's symptoms persist, a second examination should be
conducted three days later in case of false negative.31
Routine laboratory data in the early stage of EVD are
similar to that observed in common viral infection: leucopenia
(as low as 1000 cells/L), left shift with atypical lymphocytes,
thrombocytopenia (50,000e100,000 cells/L), and elevated
liver enzymes (aspartate aminotransferase typically exceeding
alanine aminotransferase). Prothrombin and partial thrombo-
plastin times are extended and fibrin split products are
detectable, indicating DIC. Leukocytosis may occur if
complicated with secondary bacterial infection.4,8 Considering
the elevated need for patient and laboratory safety, physicians
should carefully evaluate the necessity of frequent blood ex-
amination to prevent bleeding from the venipuncture site and
the risk of unexpected laboratory exposure.
6. Treatment
Currently there is no standard treatment for EVD. The main
strategies presently employed are symptomatic and supportive
care, such as preserving fluid and electrolytes balance, main-
taining oxygen saturation and blood pressure, and treating
complications such as secondary infections.
Because of the high mortality rate of EVD, many investi-
gational treatments are underway (Table 2):
1. Zmapp: This experimental drug, developed by Mapp
Biopharmaceutical, Inc., is a combination of three hu-
manized murine antibodies generated by Ebola virus
infected mice, and subsequently produced in tobacco
plants. In animal studies, forty-three percent of infected
mice survived with Zmapp treatment.32 It has been used
experimentally for some patients in the 2014 West Africa
Ebola outbreak, and several people survived. However,
because no randomized controlled clinical trials have been
undertaken, it remains inconclusive whether ZMapp is
effective for people suffering from EVD.33,34
Table 2
Investigational modalities and vaccines for Ebola virus disease treatment.
Drug Mechanism Effect
Zmapp Combined antibody binds to and inactivates virus - Protects monkeys infected with Ebola virus
- Seven people on “compassionate use”, two died
Convalescent therapy Passive immunization (neutralizing antibodies,
serum from recovered Ebola patients)
- Protective effect, in vitro
- Therapeutic effect, in rodents but fails in non-human primates
Antiviral drug
Ribavirin Interferes with capping of viral mRNA - Not recommended due to severe adverse effects
Lamivudine A nucleoside analogue that interferes gene replication - No survival benefit demonstrated in EVD
Favipiravir Broad effect antiviral compound that inhibits a viral enzyme - Protects mice with Ebola. -Phase III trials in human with influenza
Vaccine
cAd3 Segments of genetic material from two Ebola virus
species delivered by a chimpanzee virus
- Imminent phase I clinical trials
rVSV A gene from Ebola loaded in a weakened version of
vesicular stomatitis virus
- Prevents lethal infection in non-human primates
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patients): This strategy had been used to support passive
immunization. In 1976, the treatment had been used for a
woman with EVD in Zaire. Initially, her symptoms
improved but she eventually passed.35,36 Like ZMapp,
there have been no randomized controlled clinical trials
for this disease management strategy. Nevertheless, as the
Ebola epidemic remains largely uncontrolled, the World
Health Organization (WHO) was approached by several
donors, foundations, public health agencies, and develop-
ment partners to offer guidance and advice for this and
other strategies.
3. Antiviral drugs: Ribavirin and lamivudine had been tried
as a means to treat Ebola virus disease. However, ribavirin
was not recommended due to severe adverse effects that
were observed.8,37 Furthermore, there was no obvious
survival benefit for lamivudine treatment.33 Another
experimental anti-viral drug, favipiravir, was developed by
Fujifilm, Japan, initially for treating influenza virus
infection. This drug could prevent a lethal outcome in the
animal study. Given the ongoing challenges that Ebola
virus presents, further human studies are ongoing.34
4. Vaccine: There are currently two vaccine candidates,
cAd3-EBOV (cAd3) and rVSVDG-EBOV-GP (rVSV), and
both are under investigation. The cAD3 vaccine is in
Phase I trial and the rVSV vaccine had been shown to
prevent lethal infection in non-human primates. However,
their short and long-term effectiveness against the Ebola
virus in humans requires further evaluation.347. Prevention
Since there are no standard treatments for EVD, it is
important to avoid infection or further spreading of the virus.
For the general population, if travelling to any endemic area of
EVD (such as Guinea, Liberia, and Sierra Leone), contact with
or consumption of any wild animal is strongly dissuaded. For
those with a history of travel from any endemic area in the past
three weeks, body temperature should be monitored for up to
21 days.38 For healthcare workers, personal protectiveequipment should be properly put on and taken off while caring
for possible or defined patients. Safety needles are recom-
mended for venipuncture or blood examination. Once exposed
to blood or body fluids of the unprotected patient, healthcare
workers should thoroughly flush the exposure site with water or
soap. Afterward, body temperature should be monitored for
21 days. The defined case should be isolated in a negative
pressure isolation room or, alternatively, a single room with
independent sanitary wares. Under the circumstances of two
negative results within a single 48 hour period, isolation status
could be removed.39 In the event of death attributed to EVD,
corpses should be burned within 24 hours. Men who have
recovered from the disease can still transmit the virus through
their semen for up to 7 weeks after recovery.40
The Ebola virus is moderately thermolabile and susceptible
to many chemical agents, such as 3% acetic acid, 1% glutar-
aldehyde, alcohol-based products, and dilutions (1:10 to
1:100) of 5.25% household bleach (sodium hypochlorite) for
more than 10 minutes, and calcium hypochlorite (bleach
powder).41 According to the WHO recommendations, a
potentially hazardous blood spill or body fluid environment
could be cleaned up with 1:10 dilution of 5.25% household
bleach for 10 minutes. For surfaces that may corrode or
discolor, the recommendation was careful cleaning to remove
visible stains followed by contact with a 1:100 dilution of
5.25% household bleach for more than 10 minutes. Clothing or
drape with severe contamination should be burned if safe
cleaning is not feasible.38
In conclusion, Ebola virus infection is a lethal zoonotic
disease with a high mortality rate. Currently, there is no stan-
dard treatment for the disease and supportive treatment was the
only available strategy. Although many experimental trials are
underway, the best we can do to prevent a rampant outbreak in
Taiwan is stringent infection control operations. Clinicians
should consider the possibility of Ebola virus infection in
persons with travel or exposure history with the incubation
period presenting constitutional symptoms. First-line healthcare
providers should also be acutely aware of appropriate infection
prevention measures for patients whose travel, country of origin
or other contacts may make them the subject of further inquiry
and investigation now or in the future.
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